+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sickle Cell Disease Treatment Market - Global Forecast to 2030- Product Image
Sickle Cell Disease Treatment Market - Global Forecast to 2030- Product Image
Sale

Sickle Cell Disease Treatment Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6024723
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Sickle Cell Disease Treatment Market grew from USD 3.25 billion in 2024 to USD 3.74 billion in 2025. It is expected to continue growing at a CAGR of 15.77%, reaching USD 7.84 billion by 2030.

Sickle cell disease (SCD) remains one of the most challenging hereditary blood disorders, impacting millions worldwide with chronic anemia, painful vaso-occlusive crises, and a heightened risk of life-threatening complications. Despite significant advances in supportive care, the journey toward definitive cures and transformative therapies has been protracted. Recent scientific breakthroughs in gene editing, novel pharmacotherapies, and improved transplant protocols are converging to reshape the therapeutic landscape. Against a backdrop of evolving regulatory policies, shifting healthcare economics, and patient-centric care models, this executive summary distills the critical developments poised to accelerate progress in SCD management. It synthesizes the latest data on treatment paradigms, market drivers, policy impacts, segmentation dynamics, regional patterns, and competitive activity. By offering a concise, authoritative overview, this summary equips stakeholders-ranging from clinical and research leaders to commercial strategists-with the insights needed to navigate a complex environment. Key themes include the integration of curative gene therapies alongside emerging pharmacologic agents, the implications of policy changes on drug accessibility, and the strategic priorities for market entrants. Through this lens, decision-makers can chart a path toward improved patient outcomes and sustainable growth in the SCD treatment arena.

Transformative Shifts Reshaping Treatment and Access

Over the past decade, pivotal shifts have accelerated innovation in SCD treatment. Gene editing platforms have matured from theoretical constructs into clinical candidates, exemplified by CRISPR-based therapies demonstrating durable hemoglobin correction. Concurrently, the approval of novel pharmacotherapies such as L-Glutamine (Endari) and emerging voxelotor formulations have expanded the toolkit for symptom management. In the transplant arena, refinements in conditioning regimens and donor selection have boosted the safety profile of both allogeneic and autologous bone marrow procedures. The convergence of digital health, real-world evidence generation, and patient registries has reshaped trial design and post-market surveillance, emphasizing patient-reported outcomes and long-term safety. Regulatory agencies are responding with adaptive approval pathways and guidance on gene therapy governance, expediting access while maintaining rigorous oversight. Simultaneously, industry partnerships and public-private consortia are pooling expertise and capital to de-risk early-stage research. These transformative shifts reflect a broader transition from reactive, symptom-driven care to proactive, potentially curative interventions. As stakeholders embrace precision medicine principles and value-based reimbursement models, the SCD market is poised for a new era of personalized, outcome-oriented treatments.

Cumulative Impact of United States Tariffs on SCD Treatment Supply Chains

In 2025, newly imposed tariff adjustments in the United States have materially influenced the importation cost of advanced therapies and specialized reagents critical to SCD treatment development. The cumulative impact manifests in extended supply chains and incremental increases in manufacturing expenditures for gene editing vectors, bioreactor consumables, and high-purity pharmacologic ingredients. These cost pressures are transmitted through to product pricing negotiations and payer coverage decisions, often resulting in delayed formulary inclusion or heightened prior authorization requirements. Smaller biotechnology firms, operating with leaner margins, are particularly vulnerable to these shifts, prompting some to seek strategic partnerships or carve-out agreements with domestic manufacturers. Larger players have offset a portion of the tariff burden through on-shore production investments and backward integration strategies, ensuring continuity of supply for high-value orphan therapies. The net effect has been a reconfiguration of commercial strategies: accelerated domestic capacity expansion, re-evaluation of global sourcing, and renegotiation of long-term supply contracts. For clinicians and patients, these dynamics translate into potential delays in therapy availability and variable out-of-pocket expenses. As a result, stakeholders must factor in tariff-related contingencies when planning clinical development timelines, budgeting for market entry, and designing patient access programs.

Key Segmentation Insights Informing Market Prioritization

An in-depth examination of market segmentation reveals critical levers for strategic prioritization. By treatment type, blood transfusion remains a mainstay for acute and chronic management, but its share is shifting toward pharmacotherapy innovations such as Endari, hydroxyurea, and gene therapy candidates. Within bone marrow transplantation, the expansion of allogeneic transplant options and the maturation of autologous approaches underscore the movement toward curative intent. Analysis by patient age shows a bifurcation between pediatric protocols emphasizing early intervention and adult treatment plans that balance efficacy with long-term safety. Drug administration methods favor oral formulations for improved compliance, yet the promise of intravenous gene therapies necessitates investment in infusion center capabilities. Disease subtype insights highlight differentiated needs for HbSC versus HbSS populations, guiding tailored therapeutic approaches. Finally, end-user analysis underscores the critical role of hospital settings-both public and private-in delivering complex therapies, while clinics and research institutions drive outpatient management and trial enrollment. Together, these segmentation insights enable stakeholders to align R&D funding, commercial launches, and reimbursement strategies with the nuanced demands of each patient cohort and care setting.

Key Regional Insights and Their Implications for Market Access

Regional dynamics continue to shape the distribution of SCD therapies and the pace of adoption. In the Americas, robust public health infrastructure and a high prevalence of Hispanic and African-American populations drive demand for both established and novel treatments. Reimbursement frameworks that support orphan drug incentives have encouraged pipeline investment, though access disparities persist in underserved areas. Europe, Middle East & Africa present a heterogeneous landscape: established European markets exhibit streamlined pathways for gene therapies, while emerging economies in the Middle East and Africa face challenges in diagnostic capacity, cold-chain logistics, and financial coverage. Collaborative funding models and nonprofit partnerships are critical in these regions to bridge gaps. In Asia-Pacific, rapid regulatory harmonization efforts, growing biotech clusters, and expanding healthcare budgets are accelerating clinical trial activity and commercial launches. Japan and Australia lead in adopting innovative therapies, whereas India and China focus on generic pharmacotherapy production and cost-effective management solutions. Understanding these regional nuances is essential for designing market entry strategies, forging distribution alliances, and deploying patient support programs that address local barriers.

Key Company Insights and Competitive Dynamics

The competitive landscape is defined by a diverse array of biopharmaceutical innovators and established industry leaders. Smaller biotech firms specializing in gene editing, such as CRISPR Therapeutics AG, Editas Medicine, Inc., and Intellia Therapeutics, Inc., are advancing early-stage candidates that leverage precise genome modulation. Gene therapy pioneers like Bluebird Bio, Inc. and Beam Therapeutics, Inc. are translating cutting-edge research into pivotal trials, setting the stage for potential regulatory approvals. Large pharmaceutical companies-including Novartis AG, F. Hoffmann-La Roche AG, Sanofi S.A., and Bristol-Myers Squibb Company-are harnessing extensive development capabilities to optimize both novel biologics and improved small-molecule agents like hydroxyurea. Biogen Inc. and Vertex Pharmaceuticals, Inc. are pursuing adjunctive therapies aimed at reducing symptom burden and improving quality of life. Meanwhile, specialized players such as Akums Drugs and Pharmaceuticals Ltd., Emmaus Medical, Inc., GlycoMimetics, Inc., Medunik USA, Protagonist Therapeutics, Inc., Sangamo Therapeutics, Inc., and Vor Biopharma, Inc. contribute niche solutions ranging from supply-chain excellence to targeted anti-adhesion treatments. This dynamic interplay of academic spin-outs, biotech disruptors, and multinational corporations fuels continuous innovation, driving toward a future where curative options become standard of care.

Actionable Recommendations for Strategic Advancement

To capitalize on emerging opportunities and mitigate risks, industry leaders should consider the following recommendations. First, prioritize investment in domiciled manufacturing capabilities to reduce exposure to tariff fluctuations and fortify supply chain resilience. Second, adopt adaptive clinical trial designs that integrate real-world data and patient-reported outcomes, thereby accelerating regulatory engagement and market access. Third, forge cross-sector partnerships that combine gene editing expertise with established scale-up and distribution capabilities, ensuring seamless transition from bench to bedside. Fourth, tailor patient access programs to regional reimbursement environments, leveraging tiered pricing models and innovative value-based contracting. Fifth, expand educational outreach to clinicians and patients, emphasizing the long-term benefits of emerging curative therapies to drive uptake and adherence. Finally, maintain a vigilant watch on evolving policy frameworks-particularly around gene therapy governance-and engage proactively with regulators to shape pragmatic approval pathways. By executing this multi-pronged strategy, organizations can both advance therapeutic innovation and achieve sustainable commercial success.

Conclusion: Navigating Toward Transformative Patient Outcomes

In summary, the SCD treatment landscape stands at an inflection point. Scientific breakthroughs in gene editing and novel pharmacotherapies are converging with evolving policy frameworks to create unprecedented opportunities for curative interventions. However, external pressures-such as tariff-related supply chain disruptions and regional access disparities-demand vigilant strategic planning. A nuanced understanding of segmentation dynamics, regional nuances, and competitive positioning is essential for crafting robust market entry and growth strategies. Leaders who invest in agile manufacturing, data-driven development, and patient-focused access models will be best positioned to navigate uncertainty and deliver transformative therapies to those who need them most. The collective pursuit of innovation, collaboration, and equitable access promises to rewrite the story of sickle cell disease, forging a future of improved outcomes and renewed hope.

Market Segmentation & Coverage

This research report categorizes the Sickle Cell Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Blood Transfusion
    • Acute Transfusion
    • Chronic Transfusion
  • Bone Marrow Transplant
    • Allogeneic Transplant
    • Autologous Transplant
  • Pharmacotherapy
    • Endari (L-Glutamine) Treatment
    • Gene Therapy
    • Hydroxyurea Treatment
  • Adult
  • Pediatric
  • Intravenous
  • Oral
  • Hemoglobin SC Disease (HbSC)
  • Sickle Cell Anemia (HbSS)
  • Clinics
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Research Institutions

This research report categorizes the Sickle Cell Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Sickle Cell Disease Treatment Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Akums Drugs and Pharmaceuticals Ltd.
  • Beam Therapeutics, Inc.
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • Emmaus Medical, Inc.
  • F. Hoffmann-La Roche AG
  • GlycoMimetics, Inc.
  • Intellia Therapeutics, Inc.
  • Medunik USA
  • Novartis AG
  • Protagonist Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi S.A.
  • Vertex Pharmaceuticals, Inc.
  • Vor Biopharma, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Sickle Cell Disease Treatment Market, by Treatment Type
8.1. Introduction
8.2. Blood Transfusion
8.2.1. Acute Transfusion
8.2.2. Chronic Transfusion
8.3. Bone Marrow Transplant
8.3.1. Allogeneic Transplant
8.3.2. Autologous Transplant
8.4. Pharmacotherapy
8.4.1. Endari (L-Glutamine) Treatment
8.4.2. Gene Therapy
8.4.3. Hydroxyurea Treatment
9. Sickle Cell Disease Treatment Market, by Patient Age Group
9.1. Introduction
9.2. Adult
9.3. Pediatric
10. Sickle Cell Disease Treatment Market, by Drug Administration Method
10.1. Introduction
10.2. Intravenous
10.3. Oral
11. Sickle Cell Disease Treatment Market, by Disease Type
11.1. Introduction
11.2. Hemoglobin SC Disease (HbSC)
11.3. Sickle Cell Anemia (HbSS)
12. Sickle Cell Disease Treatment Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Hospitals
12.3.1. Private Hospitals
12.3.2. Public Hospitals
12.4. Research Institutions
13. Americas Sickle Cell Disease Treatment Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Sickle Cell Disease Treatment Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Sickle Cell Disease Treatment Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Akums Drugs and Pharmaceuticals Ltd.
16.3.2. Beam Therapeutics, Inc.
16.3.3. Biogen Inc.
16.3.4. Bluebird Bio, Inc.
16.3.5. Bristol-Myers Squibb Company
16.3.6. CRISPR Therapeutics AG
16.3.7. Editas Medicine, Inc.
16.3.8. Emmaus Medical, Inc.
16.3.9. F. Hoffmann-La Roche AG
16.3.10. GlycoMimetics, Inc.
16.3.11. Intellia Therapeutics, Inc.
16.3.12. Medunik USA
16.3.13. Novartis AG
16.3.14. Protagonist Therapeutics, Inc.
16.3.15. Sangamo Therapeutics, Inc.
16.3.16. Sanofi S.A.
16.3.17. Vertex Pharmaceuticals, Inc.
16.3.18. Vor Biopharma, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. SICKLE CELL DISEASE TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. SICKLE CELL DISEASE TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. SICKLE CELL DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. SICKLE CELL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. SICKLE CELL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SICKLE CELL DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ACUTE TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CHRONIC TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ENDARI (L-GLUTAMINE) TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HYDROXYUREA TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HEMOGLOBIN SC DISEASE (HBSC), BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY SICKLE CELL ANEMIA (HBSS), BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 64. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 65. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 66. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 67. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 68. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 69. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 70. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 71. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 73. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 75. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 76. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 77. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 78. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 79. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 80. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 102. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 103. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 104. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 106. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 107. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 108. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 109. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 111. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 113. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 114. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 115. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 116. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 117. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 118. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 120. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 122. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 123. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 124. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 125. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 126. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 127. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 129. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 130. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 131. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 132. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 133. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 134. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 135. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 136. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 138. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 140. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 141. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 142. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 143. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 144. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 145. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 147. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 148. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 149. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 150. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 151. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 152. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 153. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 154. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 156. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 157. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 158. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 159. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 160. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 161. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 162. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 163. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 165. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 166. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 167. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 168. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 169. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 170. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 171. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 172. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 174. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 175. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 176. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 177. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 178. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 179. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 180. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 181. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 183. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 184. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 185. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 186. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 187. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 188. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 189. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 190. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 192. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 193. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 194. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 195. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 196. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 197. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 198. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 199. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 201. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 202. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 203. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 204. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 205. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 206. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 207. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 208. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 220. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 221. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 222. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 223. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 224. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 225. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 226. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 227. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 229. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 230. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 231. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 232. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 233. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 234. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 235. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 236. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 238. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 239. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 240. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 241. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 242. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 243. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 244. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 245. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 247. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 248. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 249. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 250. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 251. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 252. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 253. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 254. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 256. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 257. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 258. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 259. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 260. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 261. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 262. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 263. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 274. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 275. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 276. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 277. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 278. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 279. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 280. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 281. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 283. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 292. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 293. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 294. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 295. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 296. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 297. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 298. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 299. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 301. NORWAY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 302. NORWAY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 303. NORWAY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 304. NORWAY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 305. NORWAY SICKLE CELL DISEA

Companies Mentioned

  • Akums Drugs and Pharmaceuticals Ltd.
  • Beam Therapeutics, Inc.
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • Emmaus Medical, Inc.
  • F. Hoffmann-La Roche AG
  • GlycoMimetics, Inc.
  • Intellia Therapeutics, Inc.
  • Medunik USA
  • Novartis AG
  • Protagonist Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi S.A.
  • Vertex Pharmaceuticals, Inc.
  • Vor Biopharma, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Sickle Cell Disease Treatment - Global Strategic Business Report - Product Image

Sickle Cell Disease Treatment - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Sickle Cell Disease Treatment Market Report by Treatment Type, End User, and Region 2024-2032 - Product Image

Sickle Cell Disease Treatment Market Report by Treatment Type, End User, and Region 2024-2032

  • Report
  • 140 Pages
  • Global
From
Sickle Cell Disease Treatment Market Report 2025 - Product Image

Sickle Cell Disease Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Sickle Cell Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Sickle Cell Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 115 Pages
  • Global
From
Sickle Cell Disease Treatment Market Report and Forecast 2024-2032 - Product Image

Sickle Cell Disease Treatment Market Report and Forecast 2024-2032

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.